Image

Melanoma Research

Featured image for “Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update”
12/08/2022

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

December 07, 2022 07:00 ET | Source: Replimune Group Inc RP1 combined with nivolumab continues to demonstrate deep and durable responses in…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting”
11/11/2022

Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting

(November 07, 2022 08:01 ET | Source: Iovance Biotherapeutics, Inc. ) Clinically Meaningful and Durable Activity in Largest Cell Therapy…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “Interview with Dr. Zeynep Eroglu, Medical Oncologist, Moffitt Cancer Center”
05/25/2022

Interview with Dr. Zeynep Eroglu, Medical Oncologist, Moffitt Cancer Center

Dr. Zeynep Eroglu is a medical oncologist at Moffitt Cancer Center in Florida. Dr. Eroglu’s research interests are translational and…
Blog - Melanoma360
, 
Melanoma Research
Featured image for “FAQ and Update on AIM at Melanoma’s International Melanoma Tissue Bank Consortium”
05/25/2022

FAQ and Update on AIM at Melanoma’s International Melanoma Tissue Bank Consortium

TISSUE IS THE ISSUE AIM at Melanoma’s major research initiative—the International Melanoma Tissue Bank Consortium (IMTBC)—is the first of its…
Blog - Melanoma360
, 
Melanoma Research
Featured image for “COVID-19 Has Created a Backlog of Undiagnosed Cancers, Including Melanoma”
05/25/2022

COVID-19 Has Created a Backlog of Undiagnosed Cancers, Including Melanoma

By Erin Bekes In a study by Dr. Antoine Eskander and colleagues described in the Journal of the National Comprehensive…
Blog - Melanoma360
, 
Melanoma Research
Featured image for “FDA Approves KEYTRUDA for Stage IIB and IIC Melanoma Patients”
12/04/2021

FDA Approves KEYTRUDA for Stage IIB and IIC Melanoma Patients

  December 4, 2021 (Richmond, California) Yesterday, Merck announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “Relatlimab/Nivolumab Application for Frontline Advanced Melanoma Validated by EMA”
10/07/2021

Relatlimab/Nivolumab Application for Frontline Advanced Melanoma Validated by EMA

October 1, 2021 Kristi Rosa REPOST from OncLive The European Medicines Agency has validated its marketing authorization application for the…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “Vaccines 2021—Major Advances in Preventing Death from Infection and Malignancy”
09/27/2021

Vaccines 2021—Major Advances in Preventing Death from Infection and Malignancy

By Kim Margolin, M.D., FACP, FASCO Vaccine background and brief history The word “vaccine” comes from the Latin word vacca…
Blog - Melanoma360
, 
In Plain English
, 
Melanoma Research
Featured image for “Immunotherapy treatment may be appropriate for patients with earlier stages of melanoma”
09/20/2021

Immunotherapy treatment may be appropriate for patients with earlier stages of melanoma

Source: University of Pittsburgh (September 20, 2021) An immunotherapy called pembrolizumab reduced cancer recurrence after surgery in patients with stage…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “USDA Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma”
09/20/2021

USDA Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma

09/20/2021 The application is based on Phase 2/3 RELATIVITY-047 trial, in which the relatlimab and nivolumab fixed-dose combination demonstrated a…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
12/08/2022

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

December 07, 2022 07:00 ET | Source: Replimune Group Inc RP1 combined with nivolumab continues to demonstrate deep and durable responses in…
Featured image for “Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
11/11/2022

Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting

(November 07, 2022 08:01 ET | Source: Iovance Biotherapeutics, Inc. ) Clinically Meaningful and Durable Activity in Largest Cell Therapy…
Featured image for “Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
05/25/2022

Interview with Dr. Zeynep Eroglu, Medical Oncologist, Moffitt Cancer Center

Dr. Zeynep Eroglu is a medical oncologist at Moffitt Cancer Center in Florida. Dr. Eroglu’s research interests are translational and…
Featured image for “Interview with Dr. Zeynep Eroglu, Medical Oncologist, Moffitt Cancer Center”
Blog - Melanoma360
 | 
Melanoma Research
05/25/2022

FAQ and Update on AIM at Melanoma’s International Melanoma Tissue Bank Consortium

TISSUE IS THE ISSUE AIM at Melanoma’s major research initiative—the International Melanoma Tissue Bank Consortium (IMTBC)—is the first of its…
Featured image for “FAQ and Update on AIM at Melanoma’s International Melanoma Tissue Bank Consortium”
Blog - Melanoma360
 | 
Melanoma Research
05/25/2022

COVID-19 Has Created a Backlog of Undiagnosed Cancers, Including Melanoma

By Erin Bekes In a study by Dr. Antoine Eskander and colleagues described in the Journal of the National Comprehensive…
Featured image for “COVID-19 Has Created a Backlog of Undiagnosed Cancers, Including Melanoma”
Blog - Melanoma360
 | 
Melanoma Research
12/04/2021

FDA Approves KEYTRUDA for Stage IIB and IIC Melanoma Patients

  December 4, 2021 (Richmond, California) Yesterday, Merck announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda…
Featured image for “FDA Approves KEYTRUDA for Stage IIB and IIC Melanoma Patients”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
10/07/2021

Relatlimab/Nivolumab Application for Frontline Advanced Melanoma Validated by EMA

October 1, 2021 Kristi Rosa REPOST from OncLive The European Medicines Agency has validated its marketing authorization application for the…
Featured image for “Relatlimab/Nivolumab Application for Frontline Advanced Melanoma Validated by EMA”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
09/27/2021

Vaccines 2021—Major Advances in Preventing Death from Infection and Malignancy

By Kim Margolin, M.D., FACP, FASCO Vaccine background and brief history The word “vaccine” comes from the Latin word vacca…
Featured image for “Vaccines 2021—Major Advances in Preventing Death from Infection and Malignancy”
Blog - Melanoma360
 | 
In Plain English
 | 
Melanoma Research
09/20/2021

Immunotherapy treatment may be appropriate for patients with earlier stages of melanoma

Source: University of Pittsburgh (September 20, 2021) An immunotherapy called pembrolizumab reduced cancer recurrence after surgery in patients with stage…
Featured image for “Immunotherapy treatment may be appropriate for patients with earlier stages of melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
09/20/2021

USDA Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma

09/20/2021 The application is based on Phase 2/3 RELATIVITY-047 trial, in which the relatlimab and nivolumab fixed-dose combination demonstrated a…
Featured image for “USDA Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research

Recent Posts

Featured image for “From a Scare to Awareness: Lindsay Willis’s Mission to Educate on Melanoma Risks”
Jul. 23, 2024

From a Scare to Awareness: Lindsay Willis’s Mission to Educate on Melanoma Risks

Featured image for “Everything Coming up Rosy is not a Health Tune”
Jul. 18, 2024

Everything Coming up Rosy is not a Health Tune

Featured image for “Ways to Give: How You Can Donate Your Birthday Through Facebook”
Jul. 10, 2024

Ways to Give: How You Can Donate Your Birthday Through Facebook

Featured image for “Beyond the Clinic Podcast: Navigating the Storm: Managing Stress and Anxiety Through Your Cancer Journey”
Jul. 10, 2024

Beyond the Clinic Podcast: Navigating the Storm: Managing Stress and Anxiety Through Your Cancer Journey

Featured image for “Summary of Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma”
Jul. 02, 2024

Summary of Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma

Filter by Tag